Eurocine Vaccines has commenced a phase I/II clinical study of the quadrivalent influenza vaccine candidate Immunose FLU, a novel nose drop formulation based on the company's technology Endocine and inactivated split antigens.
The first subjects have been dosed in the trial.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study is conducted during the present influenza season of 2016/2017.
Eurocine Vaccines CEO Dr Hans Arwidsson said: “I am impressed by the commitment and diligence showed by both our internal team and our team of contract research organisations.
"After months of preparations, we are at a very exciting point in the development."
“This important milestone will be very valuable to bring to BIO Europe 2016 in Cologne, where I will have numerous partnering meetings in a couple of weeks’ time.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEurocine Vaccines director of clinical development Dr Marie Olliver said: “After months of preparations, we are at a very exciting point in the development.
“We have been working intensely with our contract research organisations, and I am particularly satisfied that we have started the study a bit ahead of schedule."
The study is expected to release its results next year.
Image: Electron micrograph displaying Avian influenza A H5N1 viruses. Photo: courtesy of Cynthia Goldsmith.
